Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$10.17 USD
+0.60 (6.27%)
Updated May 9, 2024 04:00 PM ET
After-Market: $10.14 -0.03 (-0.29%) 6:24 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 1 - 20 ( 66 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hitching Our Wagon To ALPHA-STAR; Increasing Target to $22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimism Builds For STAR-0215 in HAE; Positive Initial Phase 1b/2 Data Set Stage For Upcoming Pivotal Studies in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await a First Look at Phase 1b/2 ALPHA-STAR Data in HAE Patients, Where Does STAR-0215 Stand?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; All Eyes on Imminent ALPHA-STAR Proof-of-Concept Data in HAE Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- HAE KOL Call Check: Revisiting The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Wishing On A STAR(-0215): Revisiting The ALPHA-STAR Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Updated Timelines Bring STAR-0215 Closer to Finish Line; Initial ALPHA-STAR Readout Expected 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Quarter Of Execution As We Await STAR-0215 Proof-of- Concept Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Little Goes a Long Way; Updated Phase 1a Data Strengthen STAR-0215''s Profile For Long-Term Dosing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New Strategic Leaf Turned Over With OX40 Transaction,Raise
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Added To As Planned with Early-Stage STAR-0310; Price Target Adjusted Down to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J